Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF) compared with placebo1 Holistic benefit: secondary endpoints showed significant and clinically meaningful improvements...
Hence then, the article about ucb presents positive results from gemz phase 3 study at aes showing fenfluramine significantly reduces countable motor seizure frequency in cdkl5 deficiency disorder was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder )
Also on site :
- My Daughter’s Friend Has a Crush on My Husband. It’s Making Us Both Deeply Uncomfortable.
- Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
- Maga’s biggest fear is coming true and Trump won’t survive it